S&P 500   4,140.06 (-0.12%)
DOW   32,832.54 (+0.09%)
QQQ   321.01 (-0.23%)
AAPL   164.93 (-0.25%)
MSFT   280.53 (-0.84%)
META   170.47 (+2.01%)
GOOGL   117.41 (-0.05%)
AMZN   139.52 (-0.91%)
TSLA   871.20 (+0.77%)
NVDA   178.15 (-6.18%)
NIO   20.18 (-0.20%)
BABA   90.95 (-1.74%)
AMD   100.06 (-2.20%)
MU   61.45 (-1.62%)
T   18.00 (-1.91%)
CGC   3.28 (+21.48%)
GE   75.19 (+1.12%)
F   15.78 (+3.14%)
DIS   109.09 (+2.31%)
AMC   24.06 (+8.48%)
PYPL   96.26 (+0.99%)
PFE   49.33 (+0.12%)
NFLX   233.37 (+2.91%)
S&P 500   4,140.06 (-0.12%)
DOW   32,832.54 (+0.09%)
QQQ   321.01 (-0.23%)
AAPL   164.93 (-0.25%)
MSFT   280.53 (-0.84%)
META   170.47 (+2.01%)
GOOGL   117.41 (-0.05%)
AMZN   139.52 (-0.91%)
TSLA   871.20 (+0.77%)
NVDA   178.15 (-6.18%)
NIO   20.18 (-0.20%)
BABA   90.95 (-1.74%)
AMD   100.06 (-2.20%)
MU   61.45 (-1.62%)
T   18.00 (-1.91%)
CGC   3.28 (+21.48%)
GE   75.19 (+1.12%)
F   15.78 (+3.14%)
DIS   109.09 (+2.31%)
AMC   24.06 (+8.48%)
PYPL   96.26 (+0.99%)
PFE   49.33 (+0.12%)
NFLX   233.37 (+2.91%)
S&P 500   4,140.06 (-0.12%)
DOW   32,832.54 (+0.09%)
QQQ   321.01 (-0.23%)
AAPL   164.93 (-0.25%)
MSFT   280.53 (-0.84%)
META   170.47 (+2.01%)
GOOGL   117.41 (-0.05%)
AMZN   139.52 (-0.91%)
TSLA   871.20 (+0.77%)
NVDA   178.15 (-6.18%)
NIO   20.18 (-0.20%)
BABA   90.95 (-1.74%)
AMD   100.06 (-2.20%)
MU   61.45 (-1.62%)
T   18.00 (-1.91%)
CGC   3.28 (+21.48%)
GE   75.19 (+1.12%)
F   15.78 (+3.14%)
DIS   109.09 (+2.31%)
AMC   24.06 (+8.48%)
PYPL   96.26 (+0.99%)
PFE   49.33 (+0.12%)
NFLX   233.37 (+2.91%)
S&P 500   4,140.06 (-0.12%)
DOW   32,832.54 (+0.09%)
QQQ   321.01 (-0.23%)
AAPL   164.93 (-0.25%)
MSFT   280.53 (-0.84%)
META   170.47 (+2.01%)
GOOGL   117.41 (-0.05%)
AMZN   139.52 (-0.91%)
TSLA   871.20 (+0.77%)
NVDA   178.15 (-6.18%)
NIO   20.18 (-0.20%)
BABA   90.95 (-1.74%)
AMD   100.06 (-2.20%)
MU   61.45 (-1.62%)
T   18.00 (-1.91%)
CGC   3.28 (+21.48%)
GE   75.19 (+1.12%)
F   15.78 (+3.14%)
DIS   109.09 (+2.31%)
AMC   24.06 (+8.48%)
PYPL   96.26 (+0.99%)
PFE   49.33 (+0.12%)
NFLX   233.37 (+2.91%)
NASDAQ:FATE

Fate Therapeutics - FATE Stock Forecast, Price & News

$34.11
+0.69 (+2.06%)
(As of 08/8/2022 03:59 PM ET)
Add
Compare
Today's Range
$33.71
$37.13
50-Day Range
$17.78
$33.42
52-Week Range
$17.10
$97.43
Volume
122,846 shs
Average Volume
1.45 million shs
Market Capitalization
$3.30 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$75.42

Fate Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
120.4% Upside
$75.42 Price Target
Short Interest
Bearish
23.44% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.70
Upright™ Environmental Score
News Sentiment
0.40mentions of Fate Therapeutics in the last 14 days
Based on 15 Articles This Week
Insider Trading
Selling Shares
$1.65 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.40) to ($4.07) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.98 out of 5 stars

Medical Sector

710th out of 1,293 stocks

Biological Products, Except Diagnostic Industry

107th out of 197 stocks

FATE stock logo

About Fate Therapeutics (NASDAQ:FATE) Stock

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Fate Therapeutics Stock Up 2.7 %

Shares of FATE traded up $0.87 during mid-day trading on Friday, hitting $33.42. The stock had a trading volume of 1,159,557 shares, compared to its average volume of 1,198,888. The company has a market cap of $3.24 billion, a PE ratio of -12.66 and a beta of 1.62. The company's fifty day simple moving average is $26.91 and its two-hundred day simple moving average is $31.36. Fate Therapeutics has a fifty-two week low of $17.10 and a fifty-two week high of $97.43.

Fate Therapeutics (NASDAQ:FATE - Get Rating) last issued its earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.78) by $0.10. The company had revenue of $18.40 million during the quarter, compared to analyst estimates of $9.01 million. Fate Therapeutics had a negative return on equity of 40.37% and a negative net margin of 371.73%. The business's revenue was up 65.2% on a year-over-year basis. During the same quarter last year, the firm earned ($0.48) EPS. Equities analysts expect that Fate Therapeutics will post -3.4 earnings per share for the current year.

Analysts Set New Price Targets

FATE has been the topic of several analyst reports. Robert W. Baird initiated coverage on Fate Therapeutics in a report on Thursday, June 2nd. They set a "neutral" rating and a $28.00 target price on the stock. Needham & Company LLC started coverage on Fate Therapeutics in a report on Thursday, July 28th. They set a "hold" rating on the stock. BMO Capital Markets upgraded Fate Therapeutics from a "market perform" rating to an "outperform" rating and lowered their price objective for the company from $50.00 to $47.00 in a research note on Monday, July 11th. Oppenheimer lowered their price objective on Fate Therapeutics from $135.00 to $90.00 in a research note on Thursday. Finally, Truist Financial lowered their price objective on Fate Therapeutics from $125.00 to $75.00 in a research note on Wednesday, April 13th. One research analyst has rated the stock with a sell rating, four have given a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat, Fate Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $75.42.

Insider Transactions at Fate Therapeutics

In related news, Director John Mendlein sold 1,364 shares of the firm's stock in a transaction that occurred on Friday, June 3rd. The stock was sold at an average price of $22.79, for a total value of $31,085.56. Following the sale, the director now owns 158,091 shares of the company's stock, valued at approximately $3,602,893.89. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, insider Mark Plavsic sold 3,719 shares of the firm's stock in a transaction that occurred on Tuesday, July 5th. The stock was sold at an average price of $24.61, for a total value of $91,524.59. Following the sale, the insider now owns 127,123 shares of the company's stock, valued at approximately $3,128,497.03. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director John Mendlein sold 1,364 shares of the firm's stock in a transaction that occurred on Friday, June 3rd. The stock was sold at an average price of $22.79, for a total value of $31,085.56. Following the completion of the sale, the director now directly owns 158,091 shares in the company, valued at approximately $3,602,893.89. The disclosure for this sale can be found here. In the last quarter, insiders sold 53,082 shares of company stock worth $1,646,106. 18.58% of the stock is currently owned by corporate insiders.

Receive FATE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FATE Stock News Headlines

Fate Therapeutics (NASDAQ:FATE) PT Lowered to $90.00
Fate Therapeutics: Q2 Earnings Insights
Expert Ratings for Fate Therapeutics
Tuesday's ETF Movers: ARKK, OIH
See More Headlines
Receive FATE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FATE Company Calendar

Last Earnings
11/04/2021
Today
8/08/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FATE
Fax
N/A
Employees
449
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$75.42
High Stock Price Forecast
$115.00
Low Stock Price Forecast
$28.00
Forecasted Upside/Downside
+121.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
12 Analysts

Profitability

Net Income
$-212,150,000.00
Net Margins
-371.73%
Pretax Margin
-371.73%

Debt

Sales & Book Value

Annual Sales
$55.85 million
Book Value
$7.11 per share

Miscellaneous

Free Float
78,977,000
Market Cap
$3.30 billion
Optionable
Optionable
Beta
1.62














FATE Stock - Frequently Asked Questions

Should I buy or sell Fate Therapeutics stock right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. There are currently 4 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FATE shares.
View FATE analyst ratings
or view top-rated stocks.

What is Fate Therapeutics' stock price forecast for 2022?

12 Wall Street research analysts have issued 1-year price targets for Fate Therapeutics' stock. Their FATE stock forecasts range from $28.00 to $115.00. On average, they anticipate the company's stock price to reach $75.42 in the next year. This suggests a possible upside of 115.9% from the stock's current price.
View analysts price targets for FATE
or view top-rated stocks among Wall Street analysts.

How has Fate Therapeutics' stock price performed in 2022?

Fate Therapeutics' stock was trading at $58.51 at the start of the year. Since then, FATE shares have decreased by 40.3% and is now trading at $34.93.
View the best growth stocks for 2022 here
.

When is Fate Therapeutics' next earnings date?

Fate Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our FATE earnings forecast
.

How were Fate Therapeutics' earnings last quarter?

Fate Therapeutics, Inc. (NASDAQ:FATE) announced its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.13. The biopharmaceutical company had revenue of $14.23 million for the quarter, compared to the consensus estimate of $8.67 million. Fate Therapeutics had a negative trailing twelve-month return on equity of 40.37% and a negative net margin of 371.73%. The firm's revenue for the quarter was up 88.3% on a year-over-year basis. During the same period last year, the firm earned ($0.36) EPS.

What is Scott Wolchko's approval rating as Fate Therapeutics' CEO?

2 employees have rated Fate Therapeutics Chief Executive Officer Scott Wolchko on Glassdoor.com. Scott Wolchko has an approval rating of 100% among the company's employees. This puts Scott Wolchko in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Fate Therapeutics own?

What is Fate Therapeutics' stock symbol?

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

Who are Fate Therapeutics' major shareholders?

Fate Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (11.87%), Sumitomo Mitsui Trust Holdings Inc. (1.31%), Nikko Asset Management Americas Inc. (1.31%), Victory Capital Management Inc. (1.11%), Brown Advisory Inc. (0.51%) and Candriam S.C.A. (0.23%). Insiders that own company stock include Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, Edward J Dulac III, J Scott Wolchko, John Mendlein, Louis T Petrillo, Mark Plavsic, Redmile Group, Llc, Shefali Agarwal and Yu-Waye Chu.
View institutional ownership trends
.

How do I buy shares of Fate Therapeutics?

Shares of FATE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fate Therapeutics' stock price today?

One share of FATE stock can currently be purchased for approximately $34.93.

How much money does Fate Therapeutics make?

Fate Therapeutics (NASDAQ:FATE) has a market capitalization of $3.38 billion and generates $55.85 million in revenue each year. The biopharmaceutical company earns $-212,150,000.00 in net income (profit) each year or ($2.64) on an earnings per share basis.

How many employees does Fate Therapeutics have?

Fate Therapeutics employs 449 workers across the globe.

How can I contact Fate Therapeutics?

Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.fatetherapeutics.com. The biopharmaceutical company can be reached via phone at (858) 875-1800 or via email at christina@sternir.com.

This page (NASDAQ:FATE) was last updated on 8/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.